Barusiban
As of the edition of 20 October 2026, Barusiban is a protein: went quiet in 2015; acts on OXTR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2015
- Kind
- Protein
- Registered trials
- 4, 0 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| OXTR | Oxytocin receptor | P30559 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 4 | 0 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Ferring Pharmaceuticals | Lead sponsor of trials | 2003 to now |